Diagnosis of non-alcoholic fatty liver disease (NAFLD) in overweight and obese women with polycystic ovary syndrome (PCOS). Metabolic associations between NAFLD and PCOS – preliminary study

Rozpoznawanie niealkoholowego stłuszczenia wątroby u kobiet z nadwagą i otyłością z zespołem policystycznych jajników. Współzależności metaboliczne między oboma zespołami – badanie wstępne

Summary

Introduction. Recent findings suggest that women with polycystic ovary syndrome (PCOS) may be at risk for developing non-alcoholic fatty liver disease (NAFLD) and conversely, hepatic steatosis may be a risk factor for PCOS.

Aim. To estimate noninvasively the prevalence of non-alcoholic fatty liver disease in overweight and obese women with polycystic ovary syndrome and to investigate potential metabolic associations between NAFLD and PCOS.

Material and methods. In 35 overweight and obese women with PCOS (19-49 years, BMI 26.8-60.2 kg/m²) aminotransferases activity was estimated and ultrasonography imaging was performed.

Results. In 17 of all subjects (48.6%) NAFLD was diagnosed. ALT and GGTP were significantly higher, and de Ritis ratio (ATP/ALT) was lower in women with NAFLD in comparison to subjects without liver steatosis, and correlated with indices of obesity. In women with NAFLD glucose, insulin and HOMA were higher than in patients without liver disease. In NAFLD patients ALT and de Ritis ratio correlated with LDL-cholesterol. ALT and GGTP correlated also with triglyceride levels. LH/FSH ratio was lower in women with NAFLD in comparison to patients without liver steatosis.

Conclusions. Non-alcoholic liver disease was diagnosed non-invasively in nearly half of overweight/obese subjects with PCOS. Non-invasive markers of liver diseases correlated with indices of obesity, glucose and lipid metabolism. Lower LH/FSH ratio in women with NAFLD may suggest, that abnormalities associated with liver steatosis additionally contribute to hormonal dysregulation in women with PCOS.

Key words
liver steatosis, obesity, polycystic ovary syndrome

Słowa kluczowe
stłuszczenie wątroby, otyłość, zespół policystycznych jajników

Address/adres:
*Jarosław Kozakowski
Department of Endocrinology
Center of Postgraduate Medical Education, Bielański Hospital, Warszawa
tel./fax +48 (22) 834-31-31
jkozakowski@cmkp.edu.pl

Wstęp. Badania wskazują, że zespół policystycznych jajników (PCOS) może zwiększać ryzyko rozwoju niealkoholowego stłuszczenia wątroby (NAFLD), i odwrotnie: stłuszczenie wątroby być czynnikiem ryzyka PCOS.

Cel pracy. Ocena częstości występowania niealkoholowego stłuszczenia wątroby (NAFLD) rozpoznawanego nieinwazyjnie u kobiet z zespołem policystycznych jajników (PCOS), a także zbadanie metabolicznych zależności między NAFLD i PCOS.

Material i metody. U 35 kobiet z nadwagą i otyłością z PCOS (19-49 lat, BMI 26.8-60.2 kg/m²) oznaczono aktywność aminotransferaz i GGTP oraz przeprowadzono badanie ultrasonograficzne.

Wyniki. U 17 z badanych (48.6%) rozpoznano NAFLD. Aktywność enzymów wskaźnikowych – AIAT i GGTP – była znamienicie wyższa, a wskaźnik de Ritis (AspAT/AIAT) niższy u badanych z NAFLD w porównaniu do kobiet bez stłuszczenia wątroby. Wskaźniki te korelowały z miernikami otyłości. U kobiet z NAFLD stężenie glukozy, insulin i wartość HOMA były wyższe niż u badanych bez stłuszczenia wątroby. AIAT i wskaźnik de Ritis, de Ritis corelated also with triglyceride levels. Wskaźnik LH/FSH był niższy u kobiet z NAFLD w porównaniu do badanych bez stłuszczenia wątroby.

Streszczenie

Wstęp. Badania wskazują, że zespół policystycznych jajników (PCOS) może zwiększać ryzyko rozwoju niealkoholowego stłuszczenia wątroby (NAFLD), i odwrotnie: stłuszczenie wątroby być czynnikiem ryzyka PCOS.

Cel pracy. Ocena częstości występowania niealkoholowego stłuszczenia wątroby (NAFLD) rozpoznawanego nieinwazyjnie u kobiet z zespołem policystycznych jajników (PCOS), a także zbadanie metabolicznych zależności między NAFLD i PCOS.

Material i metody. U 35 kobiet z nadwagą i otyłością z PCOS (19-49 lat, BMI 26.8-60.2 kg/m²) oznaczono aktywność aminotransferaz i GGTP oraz przeprowadzono badanie ultrasonograficzne.

Wyniki. U 17 z badanych (48.6%) rozpoznano NAFLD. Aktywność enzymów wskaźnikowych – AIAT i GGTP – była znamienicie wyższa, a wskaźnik de Ritis (AspAT/AIAT) niższy u badanych z NAFLD w porównaniu do kobiet bez stłuszczenia wątroby. Wskaźniki te korelowały z miernikami otyłości. U kobiet z NAFLD stężenie glukozy, insulin i wartość HOMA były wyższe niż u badanych bez stłuszczenia wątroby. AIAT i wskaźnik de Ritis korelowały także z stężeniem triglicerydów. Wskaźnik LH/FSH był niższy u kobiet z NAFLD w porównaniu do badanych bez stłuszczenia wątroby.
INTRODUCTION
Polycystic ovary syndrome (PCOS) affects as many as 1 out of 10 women in the reproductive age, and therefore is one of the most frequent endocrine disorders in this population (1). The main signs and symptoms of PCOS are irregular, but one of the important features are polycystic ovaries, usually recognize by ultrasound imaging.
Approximately 50% of the women with PCOS characterize by overweight or obesity (2). Abdominal type of obesity that is dominating in this syndrome leads to insulin resistance in patients and is a well-recognized risk factor for further metabolic and hormonal disturbances.
Non-alcoholic fatty liver disease (NAFLD) is a chronic condition also associated with insulin resistance. It is defined by detection of ectopic fat accumulation in liver, either by imaging or by histology in the absence of other identifiable causes of liver steatosis, in particular in the absence of excessive alcohol consumption (3). Patients with liver steatosis have 3-fold higher prevalence of pre-diabetes and type 2 diabetes mellitus than healthy individuals (4). Moreover, disease in this advanced state may lead to cirrhosis in 10-15% of patients.
Regarding relationships between NAFLD and PCOS elevated alanine aminotransferase (ALT) activity, one of the non-invasive markers of liver diseases is a common finding in PCOS (5).
Features of NAFLD were found in 41% of patients with PCOS (6), and it is suspected that in obese women with PCOS number of liver steatosis is even higher (7). On the other hand, signs and symptoms of PCOS in women with diagnosed NAFLD reached 71% (8). Recent findings suggest that women with polycystic ovaries may be at risk for developing non-alcoholic fatty liver disease and conversely, hepatic steatosis may be a risk factor for polycystic ovary syndrome (9).
AIM
The goal of our study was to estimate the prevalence of non-alcoholic liver disease in overweight and obese women with PCOS. We also investigated potential associations between the some non-invasive markers of liver diseases and metabolic indices as well as hormones in our patients with PCOS.
MATERIAL AND METHODS
We evaluated 35 overweight and obese women with PCOS aged 19-49 years, mean 28.7 ± 7.6 (x ± SD) with BMI 26.8-60.2 kg/m² (36.9 ± 8.0). In all subjects polycystic ovary syndrome was diagnosed according to the Rotterdam consensus criteria (10).

Other conditions with similar signs were ruled out. Clinical hyperandrogenaemia was defined as presence of hirsutism and/or acne. Biochemical hyperandrogenaemia was defined as serum testosterone levels greater than 3.1 nmol/L, dehydroepiandrosterone-sulfate levels (DHEA-S) greater than 2000-4100 ng/ml depending on age, or free androgen index (FAI) > 5. Ovaries in US were defined as polycystic when they included either 10 or more follicles measuring 2-9 mm in diameter or their volume was greater than 10 cm³ (fig. 1). Similar conditions: hyperprolactinaemia, Cushing’s syndrome or nonclassical congenital adrenal hyperplasia were excluded. Also use of oral contraceptives and other hormonal drugs excluded from the study.

Fig. 1. Example of ultrasound imaging of polycystic ovary in one of our patients (K. M.).

Non-alcoholic fatty liver disease was diagnosed according to actual criteria of American Association for the Study of Liver Diseases (AASLD) (3) which include (1) evidence of liver steatosis by imaging or by histology, and (2) no causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of statogenic medication or hereditary disorders. On the basis of US imaging concomitant with data form medical history all patients were divided into group I including subjects without fatty liver disease and group II of women with diagnosed NAFLD. In agreement with recommendations of AASLD (3) we did not performed liver biopsy in our polycystic ovaries suffering, but otherwise healthy patients.
All subjects were studied after an overnight fast. As a part of physical examination body height and
weight were measured, and then body mass index (BMI) was calculated. Blood was collected at about 0800 h for glucose, lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides), high sensitive C-reactive protein (hsCRP), alanine and aspartate aminotransferases (ALT and AST), gamma glutamyl transpeptidase (GGTP), insulin, LH, FSH, testosterone, dehydroepiandrosterone-sulfate (DHEA-S), 17-hydroxyprogesterone, sex hormone-binding globulin and TSH, through an iv catheter placed in the forearm. The liver enzymes have traditionally been used as surrogate markers of liver disease; however, their accuracy is limited. Then, we additionally calculated de Ritis ratio, as AST (IU/L)/ALT (IU/L) activity (11). Homeostasis Model of Assessment – Insulin Resistance (HOMA) was calculated by the formula: fasting plasma insulin (microinternational units per milliliter) x fasting plasma glucose (millimoles per liter)/22.4. Subjects were considered as insulin resistant when HOMA index was > 2.5. Free androgen index (FAI) was calculated as testosterone (nmol/l)/SHBG (nmol/l) levels. FAI > 5 indicated hyperandrogenemia.

All of the subjects underwent transvaginal ultrasonography (TV-US) and US of abdomen to estimate liver echogenity and to exclude adrenal pathology. In ultrasound evaluation of hepatic steatosis usually four criteria are used: parenchymal brightness, liver to kidney contrast, deep beam attenuation, bright vessel walls (12). We based on descriptions from our US department, in which hepatic steatosis or at least liver hyperechogenity were featured. Body composition was determined by dual-energy absorptiometry method (DEXA, fig. 2).

The local ethical committee approved the study and informed consent was obtained from all of the participants.

**Assays**

Glucose was measured with glucose hexokinase reagent set with sensitivity 2.16 mg/dL. An enzymatic colorimetric method was used to measure total cholesterol in the presence of cholesterol oxidase and esterase. The sensitivity was 0.116 mg/dL. HDL-cholesterol was measured with enzymatic colorimetric method; sensitivity was 3 mg/dL. Triglycerides were also measured with enzymatic colorimetric method with sensitivity 0.85 mg/dL. All mentioned enzymatic (ALT, AST, GGTP) and biochemical measurements were performed using Roche Cobas Integra 400 chemistry analyzer (Roche Diagnostics). Insulin was measured by immunoradiometric method (Insulin IRMA – Immunotech SA, France); sensitivity was 2.0 mIU/mL. TSH, LH, FSH and estradiol were measured by immunochromiluminescence method with IMMULITE 2000 (Siemens Healthcare Diagnostics, Inc); sensitivity for estradiol was 15 pg/mL. Also total testosterone was measured by immunochromiluminescence method with IMMULITE 2000 (Siemens Healthcare Diagnostics, Inc); sensitivity was 0.15 ng/ml (= 0.5 nmol/l). Results were then multiplied by factor 3.46 to obtain nmol/l. Dehydroepiandrosterone-sulfate was measured by immunochromiluminescence method with IMMULITE 2000 (Siemens Healthcare Diagnostics, Inc); sensitivity of this method was 30 ng/ml. 17-hydroxyprogesterone was measured by 17OH-RIA-CT Kit (DIAsource ImmunoAssays SA, Belgium); detection limit: 0.02 ng/ml.

Body mass index was calculated as a body weight (kg)/height (m²). To perform measurements of body composition we used Lunar Prodigy (GE Lunar, Madison, WI, USA) device, which was calibrated each day with a standardized phantom and serviced regularly. The coefficient of variation for measurements with this method is about 2%.

**Statistical analysis**

All the data are presented as the mean ± SD. The distribution of continuous variables was tested for normality by the Kolmogorov-Smirnov test. To examine bivariate relationships between data Pearson correlation or linear Spearman’s rank correlation analyses were used. Comparisons between groups with normal distribution of the data were performed by unpaired Student’s t-test, in other cases comparisons were performed by Kolmogorov-Smirnov test for two samples. For all analysis, a two-tailed P ≤ 0.05 was considered to indicate statistical significance. All calculations
were performed with the Statistica 8.0 software package (StatSoft Inc, Tulsa, OK, USA).

RESULTS

Table 1 presents anthropometric and biochemical characteristics of our patients. Group I consists of subjects with no NAFLD, while women with liver steatosis are in group II. Non-alcoholic fatty liver disease was diagnosed in seventeen (48.6%) of all our overweight and obese patients with PCOS.

Seventeen from all thirty five patients (48.6%) had symptoms of liver hyperechogenicity or steatosis in ultrasound examination. In fourteen of them elevated ALT activity were found. In all except one de Ritis ratio was below 1. Among patients with NAFLD two of all seventeen were overweight, fifteen were obese (88.2%), and nine (52.9%) morbidly obese.

ALT activity was nearly significantly, and GGTP activity was significantly higher in patients with NAFLD vs overweight/obese subjects without liver steatosis. Conversely, de Ritis ratio was significantly lower in women with NAFLD in comparison with subjects without fatty liver (fig. 3).

HOMA index was significantly higher in obese women with NAFLD in comparison to subjects without liver steatosis (p < 0.002, tab. 1). Five women in group I and fifteen in group II (88.2%) were insulin resistant according to HOMA index.

In women with NAFLD ALT and de Ritis ratio correlated significantly with BMI (r = 0.67, p < 0.02 and r = 0.71, p < 0.007, respectively, fig. 4).

Women with NAFLD had higher serum fasting insulin levels as well as HOMA index in comparison to patients without liver steatosis (p < 0.001 and p < 0.002, respectively, tab. 1). Also serum fasting glucose levels were markedly although not significantly higher in women with NAFLD (5.99 ± 2.9 and 4.90 ± 0.63 mmol/L, respectively). ALT and GGTP activity as well as de Ritis ratio correlated significantly with glucose levels (r = 0.93, p < 0.0001; r = 0.82, p = 0.005; r = 0.77, p < 0.03, respectively). There were also correlations between ALT, de Ritis ratio and LDL-cholesterol: r = 0.63, p < 0.02 and r = 0.59, p < 0.04, respectively. ALT and GGTP activity correlated with triglyceride levels: r = 0.53, p = 0.06 and r = 0.77, p < 0.03, respectively.

Table 2 shows hormonal data of our studied subjects. LH/FSH ratio was significantly higher in women with NAFLD in comparison to patients without liver steatosis. No significant correlations between estimated non-invasive markers of NAFLD and studied hormones (estradiol, testosterone, DHEA-S) were found.

Table 1. Baseline anthropometric and biochemical data of studied patients.

<table>
<thead>
<tr>
<th>N°</th>
<th>Parameters</th>
<th>All patients N = 35</th>
<th>Group I N = 18</th>
<th>Group II N = 17</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Age (years)</td>
<td>28.7 ± 7.65 (19-49)</td>
<td>26.7 ± 7.2 (20-49)</td>
<td>30.9 ± 7.7 (19-49)</td>
<td>NS</td>
</tr>
<tr>
<td>2</td>
<td>BMI (kg/m²)</td>
<td>36.9 ± 8.0 (26.8-60.2)</td>
<td>33.7 ± 4.5 (27.3-43.9)</td>
<td>40.2 ± 9.5 (26.8-60.2)</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>3</td>
<td>FM (kg)</td>
<td>47.3 ± 14.2 (26.3-82.4)</td>
<td>40.9 ± 9.35 (26.3-58.7)</td>
<td>54.2 ± 15.7 (26.6-82.4)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>4</td>
<td>ALT (IU/L)</td>
<td>33.2 ± 40.8 (12-243)</td>
<td>22.0 ± 10.7 (12-52)</td>
<td>48.8 ± 59.6 (14-243)</td>
<td>0.07</td>
</tr>
<tr>
<td>5</td>
<td>AST/ALT</td>
<td>0.9 ± 0.3 (0.59-1.75)</td>
<td>1.03 ± 0.3 (0.64-1.75)</td>
<td>0.75 ± 0.1 (0.59-1.08)</td>
<td>&lt; 0.005</td>
</tr>
<tr>
<td>6</td>
<td>GGTP (IU/L)</td>
<td>24.5 ± 16.3 (8-80)</td>
<td>18.1 ± 8.2 (8-39)</td>
<td>35.6 ± 21.2 (13-80)</td>
<td>&lt; 0.002</td>
</tr>
<tr>
<td>7</td>
<td>TC (mmol/L)</td>
<td>5.29 ± 1.05 (3.6-8.16)</td>
<td>5.41 ± 0.99 (4.2-7.9)</td>
<td>5.15 ± 1.1 (3.6-8.16)</td>
<td>NS</td>
</tr>
<tr>
<td>8</td>
<td>HDL-C (mmol/L)</td>
<td>1.22 ± 0.3 (0.77-1.78)</td>
<td>1.36 ± 0.2 (1.1-1.76)</td>
<td>1.07 ± 0.2 (0.77-1.42)</td>
<td>&lt; 0.0002</td>
</tr>
<tr>
<td>9</td>
<td>LDL-C (mmol/L)</td>
<td>3.23 ± 0.9 (1.9-5.51)</td>
<td>3.38 ± 0.9 (2.3-5.51)</td>
<td>3.07 ± 0.78 (1.9-5.2)</td>
<td>NS</td>
</tr>
<tr>
<td>10</td>
<td>TG (mmol/L)</td>
<td>1.77 ± 0.9 (0.68-4.04)</td>
<td>1.41 ± 0.6 (0.68-2.76)</td>
<td>2.14 ± 0.9 (0.89-4)</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>11</td>
<td>Glucose (mmol/L)</td>
<td>5.43 ± 2.1 (4.0-16.4)</td>
<td>4.90 ± 0.63 (4.6-6.6)</td>
<td>5.99 ± 2.9 (4.3-16.4)</td>
<td>NS</td>
</tr>
<tr>
<td>12</td>
<td>Insulin (µIU/mL)</td>
<td>13.9 ± 9.2 (2-33)</td>
<td>9.0 ± 5.9 (2-23)</td>
<td>19.06 ± 9.4 (4-33)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>13</td>
<td>HOMA</td>
<td>2.06 ± 1.5 (0.35-5.47)</td>
<td>3.33 ± 2.3 (0.35-9.86)</td>
<td>4.50 ± 2.5 (1.01-9.86)</td>
<td>&lt; 0.002</td>
</tr>
<tr>
<td>14</td>
<td>hsCRP (mg/L)</td>
<td>4.66 ± 6.39 (0.4-26.36)</td>
<td>6.16 ± 8.5 (0.4-39.6)</td>
<td>8.57 ± 10.3 (1.2-39.6)</td>
<td>NS</td>
</tr>
</tbody>
</table>

*p – difference between patients with and without NAFLD
BMI – body mass index; FM – fat mass; ALT – alanine aminotransferase; AST – aspartate aminotransferase; GGTP – gamma glutamyl transpeptidase; TC – total cholesterol; HDL-C – high-density cholesterol; LDL-C – low-density cholesterol; TG – triglycerides; HOMA – homeostasis model of assessment-insulin resistance; hsCRP – high selective C-reactive protein
In the last decades NAFLD has emerged as the important problem in developed countries. Patients with this condition typically meet the criteria of metabolic syndrome (abdominal obesity, atherogenic lipid profile, insulin resistance, glucose intolerance) and then are believed to be of increased cardiovascular risk (13). Diagnosis of NAFLD is often a challenge, as the signs and symptoms of this disease are nonspecific or absent. Although the liver biopsy remains the gold standard, recommendation to this procedure includes surmise of advanced liver fibrosis or risk of cirrhosis in selected patients (3). Hence, abdominal ultrasound is a method for screening asymptomatic patients with obesity or signs of metabolic syndrome. Also in our study we used to establish diagnosis of NAFLD on US images, in which hepatic steatosis or at least liver hyperechogenity were featured in patients with no causes for secondary hepatic fat accumulation, especially significant alcohol consumption.

Another method of visualization we used was dual-energy densitometry. We performed DEXA scans to evaluate body composition and fat mass. Approximately half of the patients with PCOS are overweight or obese (2). Insulin resistance, a crucial factor in the pathogenesis of this syndrome is seen in 50-80% of the patients (15). Abdominal obesity and insulin resistance may be regarded as the obvious key events connecting NAFLD to PCOS. In one recent study prevalence of hepatic steatosis in women with PCOS was found to be 67% and was significantly higher than in healthy controls (25%) (16). Conversely, in 71% of patients with NAFLD in reproductive age PCOS could be diagnosed according to Rotterdam criteria (8). Similarly, in our study NAFLD was present in 48.6% of all overweight and obese patients. Then, our results confirm the data published by others, that for obese patients with PCOS non-alcoholic fatty liver disease affects nearly half of them (7, 16).

The liver enzymes have traditionally been used as surrogate markers of liver diseases, with NAFLD among them. However, aminotransferases and GGTP activity has rather poor sensitivity and is often within normal limits (11, 17). Hence, AST/ALT ratio (de Ritis ratio) was calculated by some authors as a simple, but probably more sensitive non-invasive marker of liver diseases (11, 18, 19). We measured activity of liver enzymes and estimated AST/ALT ratio in purpose to get additionally confirmation of a liver dysfunction. We found, that increase in ALT and GGTP activity in obese patients with NAFLD in comparison to simply obese subjects is accompanied by parallel decrease in AST/ALT activity. It seems, that in women with PCOS and NAFLD apparent increase in ALT activity exceeds similar augmentation of activity of aspartate aminotransferase.

**DISCUSSION**

Also, polycystic ovary syndrome is one of the most common disorders in women at childbearing age (14). Again, ultrasonography is ordinary use as the method to recognize polycystic ovaries. Moreover, US imaging in diagnostic process is needed to exclude pathology of adrenal glands. In our study we successfully demonstrated liver fat accumulation and polycystic ovaries using ultrasound imaging.

In the last decades NAFLD has emerged as the important problem in developed countries. Patients with this condition typically meet the criteria of metabolic syndrome (abdominal obesity, atherogenic lipid profile, insulin resistance, glucose intolerance) and then are believed to be of increased cardiovascular risk (13). Diagnosis of NAFLD is often a challenge, as the signs and symptoms of this disease are nonspecific or absent. Although the liver biopsy remains the gold standard, recommendation to this procedure includes surmise of advanced liver fibrosis or risk of cirrhosis in selected patients (3). Hence, abdominal ultrasound is a method for screening asymptomatic patients with obesity or signs of metabolic syndrome. Also in our study we used to establish diagnosis of NAFLD on US images, in which hepatic steatosis or at least liver hyperechogenity were featured in patients with no causes for secondary hepatic fat accumulation, especially significant alcohol consumption. In the last decades NAFLD has emerged as the important problem in developed countries. Patients with this condition typically meet the criteria of metabolic syndrome (abdominal obesity, atherogenic lipid profile, insulin resistance, glucose intolerance) and then are believed to be of increased cardiovascular risk (13). Diagnosis of NAFLD is often a challenge, as the signs and symptoms of this disease are nonspecific or absent. Although the liver biopsy remains the gold standard, recommendation to this procedure includes surmise of advanced liver fibrosis or risk of cirrhosis in selected patients (3). Hence, abdominal ultrasound is a method for screening asymptomatic patients with obesity or signs of metabolic syndrome. Also in our study we used to establish diagnosis of NAFLD on US images, in which hepatic steatosis or at least liver hyperechogenity were featured in patients with no causes for secondary hepatic fat accumulation, especially significant alcohol consumption.

**Table 2. Hormonal data of studied patients.**

<table>
<thead>
<tr>
<th>No.</th>
<th>Parameters</th>
<th>All patients N = 35</th>
<th>Group I N = 18</th>
<th>Group II N = 17</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Testosterone (nmol/L)</td>
<td>3.23 ± 1.6 (0.15-7.35)</td>
<td>3.19 ± 1.5 (0.7-5.6)</td>
<td>3.26 ± 1.9 (0.15-7.3)</td>
<td>NS</td>
</tr>
<tr>
<td>2</td>
<td>DHEA-S (ng/mL)</td>
<td>2863.7 ± 1096 (518-4690)</td>
<td>2693.1 ± 992.7 (518-4150)</td>
<td>3034.4 ± 1197 (900-4690)</td>
<td>NS</td>
</tr>
<tr>
<td>3</td>
<td>17-KS (mg/24 h)</td>
<td>18.77 ± 7.4 (7.6-42)</td>
<td>17.2 ± 4.8 (7.6-26.5)</td>
<td>20.6 ± 9.5 (12-42)</td>
<td>NS</td>
</tr>
<tr>
<td>4</td>
<td>SHBG (nmol/L)</td>
<td>31.5 ± 16.8 (9.8-97)</td>
<td>34.4 ± 10.4 (20-55)</td>
<td>29.1 ± 20.6 (9.8-97)</td>
<td>NS</td>
</tr>
<tr>
<td>5</td>
<td>FAI</td>
<td>12.5 ± 8.8 (1.7-38.7)</td>
<td>9.98 ± 6.86 (1.8-28)</td>
<td>14.76 ± 10.0 (1.7-38.7)</td>
<td>0.12</td>
</tr>
<tr>
<td>6</td>
<td>LH/FSH</td>
<td>1.56 ± 1.8 (0.09-11.1)</td>
<td>2.22 ± 2.42 (0.56-11.1)</td>
<td>0.9 ± 0.4 (0.09-1.75)</td>
<td>&lt; 0.04</td>
</tr>
<tr>
<td>7</td>
<td>TSH (ulU/mL)</td>
<td>1.31 ± 0.6 (0.01-2.96)</td>
<td>1.26 ± 0.47 (0.6-1.95)</td>
<td>1.36 ± 0.7 (0.01-2.96)</td>
<td>NS</td>
</tr>
</tbody>
</table>

*P – difference between patients with and without NAFLD.

**Fig. 4.** Correlation between de Ritis ratio and BMI (kg/m²) in women with NAFLD.
ALT activity and de Ritis ratio of patients with NAFLD strongly correlated with BMI. It should not be surprised, as it is very well known from studies in general population, that NAFLD is closely linked to obesity, and is regarded as a hepatic manifestation of metabolic syndrome (20, 21). Indeed, in our patients fat mass correlated with ALT and nearly significantly with de Ritis ratio.

As it could be expected, fasting insulin levels as well as HOMA index were significantly higher in our patients with PCOS and NAFLD in comparison to simply overweight/obese subjects. It was already demonstrated, that muscle’s insulin resistance, which predispose to hepatic resistance to insulin was strongly linked to NAFLD in PCOS patients (22). Insulin-resistant subjects stores energy in liver triglycerides. This process leads to excessive fat production and liver steatosis. It was proved, that insulin resistance led to 2.2-fold greater de novo triglycerides lipogenesis in comparison to insulin sensitive conditions (23). As our NAFLD patients had significantly higher HOMA index in comparison to subjects without liver steatosis it could be speculated that also in patients with NAFLD and PCOS insulin resistance contributes to more intensive hepatic de novo triglycerides lipogenesis.

In our patients with NAFLD HDL-cholesterol levels were significantly lower and triglycerides levels were significantly higher than in subjects without liver steatosis. Moreover, ALT and GGTP activity as well as de Ritis ratio correlated with LDL-cholesterol levels. ALT and GGTP activity correlated with triglycerides levels. It was previously proved in general population, that dyslipidemia in NAFLD is most frequently characterized by low high-density lipoprotein cholesterol and elevated serum triglycerides (24). On the other hand, patients with high ALT activity and elevated triglycerides as well as cholesterol levels have over 80% chance of developing NAFLD (25).

Finally, we found, that in patients with PCOS and NFLD LH/FSH ratio was lower in comparison to subjects without liver steatosis. In several recent studies higher LH pulse and amplitude in women with PCOS were shown. Although a higher luteinizing hormone level drives the ovarian theca cells to produce more androgens, FSH deficiency may be the more important cause of anovulation. In most women with PCOS LH levels are elevated or the LH/FSH ratio is high. However, the mean LH pulse amplitude is attenuated in obese women with PCOS (26). Thus, a higher BMI and increased fat mass of our patients with NAFLD may explain the lower LH/FSH ratio compared to patients without the NAFLD.

There some limitation of our study that should be taken into consideration. First, it includes relatively small number of studied patients. It may be the main reason of some only nearly significant, although apparently strong correlations. Secondly, it suffers from lack of an adequate control group of healthy women. However, in this study we addressed the issue of non-alcoholic liver disease in group of obese patients with PCOS, taking into account pathogenetic associations. But we did not aim at compare prevalence of NAFLD in patients with polycystic ovaries and healthy subjects. Thirdly, our diagnostic criteria of NAFLD probably may be debatable. However, we did not decide to perform liver biopsy in our polycystic ovaries suffering, but otherwise healthy young patients.

**In conclusion**, NAFLD was diagnosed in nearly half of all studied overweight/obese women with polycystic ovary syndrome. Non-invasive markers of liver diseases were significantly higher in women with NAFLD in comparison to obese women without liver steatosis, and correlated with indices of obesity, glucose and lipid metabolism. Lower LH/FSH ratio in women with NAFLD suggests, that abnormalities associated with liver steatosis additionally contribute to hormonal dysregulation in women with PCOS.

**BIBLIOGRAPHY**


received/otrzymano: 15.10.2014
accepted/zaakceptowano: 07.11.2014